IRIS
D'ALESSIO, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 755
AS - Asia 737
EU - Europa 549
SA - Sud America 98
AF - Africa 51
Continente sconosciuto - Info sul continente non disponibili 28
OC - Oceania 3
Totale 2.221
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 712
SG - Singapore 264
RU - Federazione Russa 255
HK - Hong Kong 148
CN - Cina 138
BR - Brasile 86
IT - Italia 73
VN - Vietnam 73
DE - Germania 50
FR - Francia 45
BJ - Benin 37
GB - Regno Unito 30
KR - Corea 24
IN - India 23
CA - Canada 20
AT - Austria 17
BD - Bangladesh 14
JP - Giappone 14
MX - Messico 13
IE - Irlanda 12
NL - Olanda 12
SE - Svezia 9
FI - Finlandia 8
PL - Polonia 8
UA - Ucraina 8
TR - Turchia 6
ES - Italia 5
PK - Pakistan 5
AE - Emirati Arabi Uniti 4
AR - Argentina 4
CO - Colombia 4
CZ - Repubblica Ceca 4
LT - Lituania 4
ZA - Sudafrica 4
EG - Egitto 3
IQ - Iraq 3
JM - Giamaica 3
MA - Marocco 3
AU - Australia 2
BG - Bulgaria 2
CH - Svizzera 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EC - Ecuador 2
ID - Indonesia 2
IL - Israele 2
MY - Malesia 2
NP - Nepal 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
TH - Thailandia 2
UZ - Uzbekistan 2
AM - Armenia 1
AZ - Azerbaigian 1
BE - Belgio 1
BS - Bahamas 1
CR - Costa Rica 1
GD - Grenada 1
KZ - Kazakistan 1
LY - Libia 1
NR - Nauru 1
OM - Oman 1
PH - Filippine 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
VE - Venezuela 1
Totale 2.193
Salva come PNG Salva come JPEG
Città #
Hong Kong 148
Singapore 125
San Jose 110
Ashburn 81
Council Bluffs 75
Beijing 39
Cotonou 37
Los Angeles 34
Columbus 28
Ho Chi Minh City 28
Moscow 27
Santa Clara 27
Lauterbourg 24
New York 22
Seoul 22
Hanoi 17
Falkenstein 16
São Paulo 16
Nuremberg 13
Tokyo 13
Assago 12
Buffalo 12
Chicago 12
Dublin 12
Denver 11
Clifton 10
Chennai 9
Frankfurt am Main 9
Mexico City 9
Stockholm 9
Vienna 9
Amsterdam 8
Brooklyn 8
Helsinki 8
St Louis 8
London 7
Manchester 7
Orem 7
Phoenix 7
Warsaw 7
Ankara 6
Boston 6
Toronto 6
Boardman 5
Da Nang 5
Hangzhou 5
Milan 5
Piscataway 5
Poplar 5
Tianjin 5
Turin 5
Atlanta 4
Florence 4
Mezzomerico 4
Novara 4
Rome 4
Roubaix 4
Belo Horizonte 3
Cleveland 3
Dallas 3
Galliate 3
Houston 3
Johannesburg 3
Montreal 3
Munich 3
Pardubice 3
Suzhou 3
The Dalles 3
Uberlândia 3
Wuhan 3
Baghdad 2
Bexley 2
Cairo 2
Calimaya 2
Charlotte 2
Concord 2
Concórdia 2
Contagem 2
Corona 2
Deiva Marina 2
Delhi 2
Haiphong 2
Hải Dương 2
Kathmandu 2
Louisville 2
Medellín 2
Mumbai 2
New Delhi 2
North Charleston 2
Paris 2
Providence 2
Quito 2
Recife 2
San Francisco 2
Santa Fe 2
Secaucus 2
Shanghai 2
Sydney 2
Sylmar 2
Tashkent 2
Totale 1.264
Salva come PNG Salva come JPEG
Nome #
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 127
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 113
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 110
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 104
Effective and organ doses in patient undergoing interventional neuroradiology procedures: A multicentre study 103
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 92
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 90
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 88
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 87
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 85
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 85
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 84
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 82
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma 82
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 77
Cumulative radiation exposure from radiological imaging in patients with Hodgkin and diffuse large b-cell lymphoma not submitted to radiotherapy 76
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 74
. Optimisation of protection in the medical exposure of recurrent adult patients due to computed tomography procedures: development of recurrent exposures reference levels. 72
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 72
Differential prognostic effect of systemic inflammation in patients with non–small cell lung cancer treated with immunotherapy or chemotherapy: A post hoc analysis of the phase 3 OAK trial 72
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 70
Reply 69
Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma 69
The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma 63
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study 63
Reply 57
Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer 55
Totale 2.221
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.451
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.451
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024125 30 0 10 7 20 0 14 4 0 3 5 32
2024/2025490 6 2 46 4 5 66 58 41 76 79 32 75
2025/20261.466 61 51 69 166 210 123 205 200 107 91 137 46
2026/2027140 57 83 0 0 0 0 0 0 0 0 0 0
Totale 2.221